Drug & intervention

decitabine

RxCUI 15657

Clinical trials10
Recruiting0
Related conditions20
Synonyms12

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Decitabine

Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). Chemically, it is a cytidine analog.

Read on Wikipedia ↗ Wikidata Q1181878 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

10 shown
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate CancerNCT03709550 · 2021-04-15
WITHDRAWN
Decitabine Plus Carboplatin in the Treatment of Metastatic TNBCNCT03295552 · 2017-11-15
TERMINATED
Clinical Study of Decitabine and Paclitaxel Combination TherapyNCT03282825 · 2017-03-28
UNKNOWN
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaNCT02957968 · 2017-01-24
ACTIVE_NOT_RECRUITING
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesNCT02608268 · 2015-11-23
TERMINATED
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung CancerNCT00084981 · 2004-04-01
COMPLETED
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural MalignanciesNCT00037817 · 2002-05-17
COMPLETED
Decitabine in Treating Patients With Advanced Solid TumorsNCT00030615 · 2001-12-01
COMPLETED
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)NCT00000623 · 2000-07-01
COMPLETED
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the PleuraNCT00019825 · 1999-10-01
COMPLETED

Conditions being studied

Advanced Breast Cancer1Advanced Esophageal Cancers1Advanced Malignancies1Anemia, Cooley's1Beta-Thalassemia1Breast Adenocarcinoma1Breast Neoplasm1Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura1Castration Levels of Testosterone1Castration-Resistant Prostate Carcinoma1Esophageal Cancer1Estrogen Receptor- Negative Breast Cancer1Estrogen Receptor-positive Breast Cancer1Hematologic Diseases1HER2/Neu Negative1Hypertension, Pulmonary1Invasive Breast Carcinoma1Iron Overload1Lung Cancer1Male Breast Cancer1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.